LongBio Pharma-B Vertical and Horizontal Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing market, or creating an entirely new one?4/10

  A

  Conclusion first: measured with the Baillie Gifford LTGG yardstick of "finding ten-year five-baggers and asking why the market has not realized it," LongBio's ceiling is high enough, but its nature is "taking share from an already large pie + raising China's extremely low biologics penetration," not opening a brand-new market. LP-003 targets allergic rhinitis, CSU, and asthma. The mechanism (anti-IgE), clinical-guideline status, and payment logic are already mature. The report itself says this plainly: it is "not creating a new mechanism, but trying to make the mature anti-IgE mechanism stronger, faster, and longer-acting as a next-generation version," directly competing for "doctors' prescription share from existing anti-IgE therapies and adjacent biologics." So the ceiling is approximately China's reachable market size in major allergy (rhinitis/CSU/asthma) + complement diseases (PNH) × the penetration rate it can win, not demand appearing from nowhere.

  First size the pie. From an upside perspective, it is indeed not small. The first piece is allergy. China had about 240 million allergic rhinitis patients in 2021, and the global allergic rhinitis drug market was about 16.1 billion dollars in 2025. Within that, the anti-IgE biologics branch represented by omalizumab was about 3.0 billion dollars globally in 2025. The second piece is chronic spontaneous urticaria (CSU, the indication where LP-003 won head-to-head): the global market was about 1.25 billion dollars in 2024, with Asia-Pacific accounting for about 25%, and prevalence is about 1% of the population. The third piece is PNH, addressed by LP-005. This is a true rare disease with high unit price: the global PNH treatment market was about 5.75 billion dollars in 2024, and China is the largest single market in Asia-Pacific. Putting these together, over a ten-year horizon LP-003+LP-005 theoretically touches a domestic terminal market of "tens of billions of RMB."

  "Why has the market not realized it?" The real blue-sky lever is penetration, not patient count. LTGG cares most about upside the market has not fully priced. For LongBio, the underappreciated point is not that there are many patients, which everyone knows, but that China's biologics penetration is extremely low and far from saturated. In China, omalizumab was once the only approved anti-IgE biologic for moderate-to-severe allergic asthma, and overall biosimilar penetration remains clearly below Europe and the United States. In other words, among hundreds of millions of allergy patients, the share actually using biologics is still in the single digits. This space to "raise penetration" is the largest order-of-magnitude variable in the upside case, and the one most likely to be overlooked by the market. If LP-003 uses a longer dosing interval (lower injection frequency) and better efficacy to make biologics more accessible rather than "hard to afford and hard to adhere to," it would not only enlarge its own share, but also grow the entire biologics pie. That is the part closest to LTGG's spirit of "creating incremental growth."

  But honestly, this pie is "shared at the same table," not enjoyed alone. Even if the upside scenario is fully stretched, LongBio must compete at the same table with 3 categories of rivals: the omalizumab originator (Roche/Novartis), domestic anti-IgE biosimilars already on the market (the report notes Mabpharm's CMAB007 was approved in 2023), and IL-4Rα monoclonal antibodies with a new mechanism. Keymed's CM310 (stapokibart) became the world's first IL-4Rα antagonist approved for seasonal allergic rhinitis in February 2025, and Keymed is one of the comparable companies listed in the report. In other words, the ceiling is high, but the portion LongBio can keep depends on whether it can turn head-to-head clinical advantage into prescriptions and payment amid competition from "originator + biosimilars + new mechanisms." This is exactly the core concern repeatedly emphasized by the report and the reason it assigns a "Watch" rating and sets the margin of safety at zero.

  Finally, the tension in the LTGG yardstick itself has to be made explicit: Baillie Gifford LTGG prefers large-cap growth companies that can become hundreds-of-billions businesses and five-bag over ten years. Its portfolio is highly concentrated and rarely bets on early small-cap names like this. At LongBio's IPO price of HK$96.06, the implied market cap is only about HK$7.127 billion (about 900 million dollars), far below the market-cap scale of typical holdings. This cuts both ways. On one hand, it is small enough that the theoretical room for a "ten-year five-bagger" naturally exists, matching LTGG's preference for upside slope. On the other hand, LTGG truly bets on winners already validated with widening moats, while LongBio currently has zero revenue, zero commercialization validation, and value highly concentrated in the single LP-003 asset. By LTGG's great-growth-company standard, it is now more of a candidate "still needing to prove it can enter the list" than a qualified member. The ceiling is high enough; whether it can reach it depends on BLA, uptake, and the LP-005 second curve landing one by one.

  Jun 4, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?5/10

  A

  Conclusion first: for a company like LongBio, "can revenue double over five years" is really a false question. Its current revenue is zero, and doubling zero is still zero; the framing itself does not hold. The real question is different: over the next five years, can it go from 0 to a "meaningful scale" of revenue? My view is: starting from zero is almost certain, as long as the IPO completes smoothly and LP-003 does not derail, but whether revenue can become large within five years depends almost entirely on one thing: whether the LP-003 rhinitis BLA is approved on schedule and whether the product can scale after approval. And if that revenue line does truly start, the source of growth is also clear: almost entirely "volume," not "price," and not yet a mature "new business." Details follow.

  Step 1: put the zero base in its proper place. The report is blunt: LongBio had zero product sales revenue and zero profit in both 2024 and 2025, and its business model "has not truly started turning." So applying any "doubling/multiple" growth rate to it has no anchor. The denominator is 0, so the formula does not work. It currently lives not on revenue, but on equity financing and borrowings to support R&D. Put differently, the company's revenue story over the next five years is not "from A to 2A," but "from nothing to something": the first step is whether there is a first drug revenue, and only then can scale and slope be discussed.

  Step 2: assess how credible the "from 0 to something" path is, and how long it takes. The report's roadmap is clear: LP-003's Phase III trial in seasonal allergic rhinitis has completed enrollment, and the company plans to submit the BLA to the NMPA in or before the third quarter of 2026. In an optimistic scenario, approval comes around 2027, making it the company's first commercial product and bringing the first truly meaningful drug revenue. It would then expand along indications: CSU (chronic spontaneous urticaria, where Phase II head-to-head data have already beaten omalizumab), asthma, nasal polyps, and food allergy. These indications share related mechanisms, and doctor education can be replicated. After approval, medical-insurance/payment access could further drive penetration. In other words, the five-year window neatly covers the entire stretch from "filing → approval → first-year uptake → indication expansion + potential medical-insurance-driven volume", theoretically enough to move revenue from 0 to a respectable scale. But everything depends on the first link. The report repeatedly emphasizes that value is highly concentrated in LP-003, and the most fragile assumption is whether the rhinitis BLA can be submitted and form approval expectations around 2026Q3 as planned. If it is delayed or fails to scale after approval, the maximum loss risk is 40%–60%, and the revenue story will be pushed back wholesale. So the honest formulation is: the starting point is almost certainly zero, and whether the endpoint becomes large is a high-variance event, not a growth curve that can be extrapolated.

  Step 3: answer directly: volume, price, or new business? The answer is overwhelmingly "volume". Here, "volume" means new indication approvals + post-approval prescription penetration (more hospital coverage, more doctor prescriptions, more patients treated, and medical-insurance inclusion to broaden access).

  • Not driven by "price." LP-003 is not entering a blank market. It is competing for prescription share against omalizumab (and its domestic substitutes, such as Mabpharm's marketed CMAB007) and adjacent-pathway biologics. The report describes it as a "late-stage challenger niche player." In a market with an originator and local competitors, raising prices to drive revenue is neither realistic nor the logic. Its pitch is differentiated efficacy that is "stronger and longer-acting," not pricing power.
  • Nor is there a mature "new business" yet. LP-005 (a C5/C3b bifunctional complement fusion protein) is still in Phase II for PNH in China. The report says clearly that it is more of a "platform backup," far from contributing revenue. It is an "option" on a second growth curve, not a realistic revenue source over the next five years.

  Finally, a reference point and a risk note. Qyuns-B (02509.HK), named in the report, is a ready example of "rapid scale from a low base": 2025 total revenue was 807 million yuan, up about 408% year on year, and the company turned profitable with net profit of about 307 million yuan. This shows that an 18A company, on the right timetable, can indeed push revenue from a very low base to the 800 million+ range within one or two years. That is the path implied by LongBio's optimistic scenario (HK$141.5 per share, with valuation shifting from a "R&D story" to a "commercialization story"). But one key difference matters: of Qyuns's 800 million, nearly 90% came from out-licensing (licensing income), while actual product-supply revenue was only about 9 million yuan. In other words, an 18A company's "revenue scale-up" does not necessarily mean "drug sales volume"; it can also come from license-out transactions. LongBio's prospectus places the revenue focus on LP-003's own product sales, which is the slower route of "selling drugs" and requires commercialization capability. Summed up: LongBio's revenue over the next five years will likely start from zero. Whether it becomes large depends on approval and uptake of the single product LP-003. Growth will come almost entirely from "volume" (new approvals + penetration); "price" is basically not on the table, and "new business" (LP-005 or potential licensing) is more of an upside option than a firm contribution.

  Jun 4, 2026
• QAfter five years, what will take over as the next growth engine? Does this "second curve" exist today?3/10

  A

  Conclusion first: the seed of a second curve has indeed been planted today, but it is not yet fair to say it "already exists." At this point it is a platform + LP-005 story, not a growth curve validated by data and able to support valuation independently. Whether it can truly take over depends almost entirely on POC (proof-of-concept) data over the next 3–5 years. From a Baillie Gifford perspective, this is exactly the point investors should watch most closely, yet it is also the point most easily drowned out by the near-term noise around the rhinitis BLA.

  First define the boundary of the first curve. The market's current bet, LP-003 anti-IgE, is not just one indication. It is a "mechanism + multi-indication ladder": rhinitis leads, followed by CSU (chronic spontaneous urticaria, where Phase II head-to-head data showed a week 12 UAS7=0 rate of 66.7% in the 200mg Q8W group vs omalizumab's 43.6%), asthma, nasal polyps, and food allergy, all extendable along the same mechanism. In other words, over the next 3–7 years LP-003 itself already has internal "indication relay" depth, and that line's ceiling is far from reached. Clarifying this matters: a true "second curve" means an independent growth pole outside the LP-003 anti-IgE system.

  There are two real second-curve candidates, with different quality. ① LP-005: a bifunctional complement fusion protein targeting both C5/C3b, currently in Phase II in China for PNH (paroxysmal nocturnal hemoglobinuria), with mechanistic extension potential into complement-mediated kidney diseases. Complement is a higher-technical-barrier, higher-price field, with Apellis as the overseas benchmark. If POC works, it would provide not just a pipeline, but a new platform premium. But honestly, it is still relatively early in Phase II today. While the report defines it as a "second-curve value anchor," it also says it is "still far from standing independently in valuation." I fully agree: right now it looks more like a high-payoff option than an engine already turned on. ② The self-developed antibody platform: a high-affinity antibody discovery platform + a bifunctional antibody development platform. These two platforms are the foundation that truly determines whether "takeover capability" is sustainable. LP-003 and LP-005 are both outputs of them, and in theory they can continue to generate new molecules. The platform's value is not in any single pipeline, but in whether it can repeatedly produce druggable assets.

  Framed in Baillie Gifford's question: why has the market not realized it? Because almost all attention is currently absorbed by the 12–18 month near-term event of "whether the rhinitis BLA can be filed around 2026Q3." The valuation anchor, oversubscription multiple, and cornerstone subscriptions are all about the first shot. The real long-term upside is not there, but in the barely priced hidden line of the complement platform. In the report's optimistic scenario (about HK$141.5 per share), "LP-005 PNH data continue to improve and the market is willing to assign a higher platform premium" is explicitly listed as a key catalyst, showing that this value is basically being thrown in for free today. The risk is symmetric: the report also lists "weak LP-005 PNH/kidney disease POC" as a specific risk that would cause a "discount to the second growth curve and lower platform premium."

  So my view is: the second curve has seeds (LP-005 + two platforms), but today there is no validated curve yet. The tracking points for a Baillie-style long-term investor are clear: do not only watch the stock price and rhinitis progress. Watch LP-005 PNH Phase II hard endpoints (Hb, LDH, improvement in transfusion dependence), whether complement kidney-disease projects are launched, and whether the platform continues to produce new INDs. Once these data turn positive, the "platform story" can be upgraded from backup to a true second growth engine. If the company only shows rhinitis uptake for a long time without a second platform pillar, its growth narrative will narrow back to "single-asset commercialization," exactly the outcome the Baillie framework least wants to see.

  Jun 4, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?4/10

  A

  Conclusion first: LongBio's core competitive advantage is "differentiation on the mature anti-IgE mechanism": higher affinity, stronger blocking activity, longer dosing interval, plus Sun Naichao's know-how from participating in the invention of omalizumab and the company's self-developed antibody platform. But this moat currently looks more like an "embryonic technical barrier" than a deep trench tested by commercial war. As for whether it will widen or narrow over the next three to five years, the direction is frankly not locked. It depends entirely on whether LP-003 can obtain BLA on schedule and, after approval, turn clinical advantage into prescription and payment advantage. Before that, it is more likely to go through a period of intensifying competition first. This is consistent with the report's "moat: medium" characterization and its judgment that "it has the embryonic form of a technical barrier, but has not yet been validated in commercial war."

  The path for the moat to "widen" is clear, but it all needs delivery first. The CSU Phase II head-to-head data in the report already provide the first hard evidence: the 200mg Q8W group had a week 12 UAS7=0 rate of 66.7%, higher than omalizumab's 43.6%. If the LP-003 seasonal allergic rhinitis BLA is successfully submitted and approved around 2026Q3, and if the real world validates "better efficacy + longer dosing interval" for doctors and patients, indications expand step by step from rhinitis to CSU, asthma, nasal polyps, and food allergy, and the product eventually enters medical insurance and scales, then data barriers, brand recognition, and indication breadth can stack layer by layer. The moat can indeed widen. That is exactly the "from R&D story to commercialization story" represented by the report's optimistic scenario (HK$141.5). Put differently, widening does not come from the mechanism itself, but from turning the mechanism into prescriptions.

  But it is equally true that the forces narrowing the moat are more concrete and closer today. I tend to think this moat will first be squeezed over the next one to two years, mainly by three forces. First, strong adjacent-pathway rivals have already landed ahead of it: Keymed's stapokibart (IL-4Rα mechanism) was already approved for seasonal allergic rhinitis in February 2025, which is LP-003's first-launch indication, and it has already been included in the 2025 national medical-insurance catalog, effective 2026-01-01, giving it clear payment-access lead over LP-003. Second, next-generation anti-IgE rivals with the same mechanism are chasing: Jemincare's JYB1904 also claims better efficacy than omalizumab, has obtained about 700 million dollars in overseas licensing, and its CSU Phase II data are expected to read out in the first half of 2026, directly challenging LP-003's differentiation narrative. Third, omalizumab's own "price floor" is sinking: Mabpharm's CMAB007 (the first copy in 2023), CSPC's Enyitan (approved for asthma in 2025), and other biosimilars are arriving, while Grand Pharma is still in Phase III. That means when LP-003 launches, it will face not only the originator, but increasingly cheap domestic substitutes. The report also points to this risk of "originator and local substitutes coexisting."

  So it is clearer to separate "how deep is it" from "will it widen or narrow": statically, LongBio's technology and team advantage are real and above medium; dynamically, before LP-003 is truly approved and its advantage is solidified through real-world data and payment access, it faces a setup where a rival is already one step ahead in medical insurance, same-mechanism followers are close behind, and prices are dragged down by biosimilars. This is also why the report sets the rating at "Watch" and identifies the most fragile assumption as "whether the LP-003 rhinitis BLA can be filed and approved on schedule." My view: the moat has a real option to "widen," but the switch is held by BLA and commercialization execution. Before that key turns, the more realistic expectation is intensified competition first, not automatic thickening of the barrier.

  Jun 4, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?3/10

  A

  Conclusion first: LongBio is indeed not a "single-molecule company". It has some DNA for reinvention, but that DNA still sits at the level of "reusable technology platform" and has not been validated by a case where the core asset truly failed and the company successfully turned itself around with what remained. As for "how it handles mistakes and bad news," because the company has only just reached the listing stage and has almost no public record of bad news to examine, today we can only see some positive signs from the way it discloses information. We cannot draw a conclusion tested through a cycle.

  Start with the "reinvention DNA" side, which is somewhat positive. LongBio's base is not one drug, but two self-developed antibody platforms: a high-affinity antibody discovery platform and a bifunctional antibody development platform. The report repeatedly emphasizes that it "continues to accumulate around two immunology platforms," rather than being a "multi-project stall-style biotech." Public information shows that the high-affinity platform has produced multiple picomolar blocking monoclonal antibodies including LP-003, and LP-005 from the bifunctional platform is exploring not only PNH, but also complement-mediated kidney diseases, eye diseases, neurological diseases, and other directions. Even looking only at LP-003, its pipeline indications include rhinitis, chronic urticaria (CSU), asthma, food allergy, and others. This means that if LP-003's rhinitis indication is set back, the company theoretically still has two fallback paths: "change indication" and "change platform target." The platform's drug-development capability would not go to zero with a single pipeline. That is the biggest difference between it and a "one molecule, one company" setup.

  But this fallback has two hard constraints that must be stated clearly. The first is money and time window. The report is very direct: value is highly concentrated in LP-003. In 2025, net cash outflow from operating activities was 121 million yuan, R&D cost was 126.6 million yuan, year-end cash and cash equivalents were only 95.05 million yuan, and FVTPL financial assets were 60.11 million yuan. The company's own estimate is that cash plus financial assets can support only about 13 months; including 10% of IPO net proceeds extends this to about 21 months. In other words, "turning around" is not impossible, but it must turn before the cash runway burns out. If the LP-003 rhinitis BLA is materially delayed, the company will likely be forced into dilutive refinancing at an unfavorable valuation. The report lists this as a standalone risk and sets the corresponding maximum loss risk at 40%–60%. The second is that "reinvention" itself has never been validated. LP-005 is currently more of a "second-curve candidate" supported by mechanism and early data, and the report clearly says it is "still far from standing independently in valuation." So the more accurate statement is: it has the tools for reinvention (platforms), but has not yet proven the reinvention outcome.

  Now turn to "how it handles mistakes and bad news." Evidence is limited, so I would reserve judgment honestly. The positive signal visible today is relatively standardized disclosure. For the critical CSU head-to-head data, the company did not merely issue a press release; it publicly registered the trial on clinical registries (CTR20233300 / NCT06228560) and disclosed the full study design and endpoints at the AAAAI international academic meeting (202 patients, randomized double-blind, with omalizumab as active comparator). The prospectus also gives fairly full disclosure of adverse facts such as zero revenue, zero profit, cash burn, concentrated control, and residual pre-listing special rights. These are proxy indicators for "willingness to say the uncomfortable things upfront." But the key limitation is that the company is expected to list only on 2026-06-05, has almost no public-company history, and has not yet experienced a real bad-news event such as a failed key clinical readout, BLA rejection, or safety incident. The most convincing evidence for how a company "handles bad news" is exactly how it discloses and adjusts when bad news occurs, and that is precisely what LongBio still lacks as a public record. In other words, today we can see its "disclosure posture in a favorable game," but not its "record through an adverse game." This will become more meaningful only after it lists and encounters its first unfavorable data point.

  Jun 4, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for the next five to ten years?5/10

  A

  Conclusion first: measured by Baillie Gifford's yardstick of "founder long-term alignment," LongBio's management largely has long-term vision and aligned interests, but it is not a perfect score. It carries two governance questions that require continued monitoring. In one sentence: this is a founding team with a strong long-termist base, but with small tensions around succession and certain individual actions. It fits Baillie Gifford's preference for "people willing to walk with the company for ten years," but cannot yet provide the comfort of "complete flawlessness."

  Start with the alignment and long-term perspective, where several pieces of evidence are positive. First, interest alignment is deep enough: the report discloses that after issuance, Liu Heng and persons acting in concert will still control about 35.7% of the shares. The founding team did not dilute itself into "employees" at the listing stage; control rights and personal wealth remain tightly tied to the company's fate. Second, long-termism is almost written into the company's DNA: co-founder Sun Naichao, who is responsible for overall R&D strategy, was a co-founder of Tanox in the United States in the 1980s and one of the main inventors of the first-generation anti-IgE antibody omalizumab (Xolair). Today, at 89 years old, he still oversees the group's overall R&D strategy as an executive director. Someone who has put decades of his career into the "anti-IgE" mechanism path and continues to lead a next-generation product after retirement age is exactly the kind of "embodiment of a long-term narrative" that Baillie values. Third, from a financial-behavior perspective, this company is already "sacrificing current profit for five to ten years later": the report shows a 2025 total comprehensive loss of 175.6 million yuan, R&D cost of 126.6 million yuan, net operating cash outflow of 121 million yuan, and about 75% of net proceeds going into LP-003/LP-005 R&D and commercialization. This is not the posture of "making a quick profit." It is the typical long-cycle cash-burn bet on core assets. For a Baillie-style framework, a biotech losing money for years to fund R&D is precisely the most direct footnote to "giving up the present for the long term."

  But the other side should also be stated honestly. Two tensions cannot be hidden. The first is succession uncertainty. The company's technical soul is an 89-year-old scientist. That is a plus for "willingness to pay for ten years later," but it is also a clear question mark for whether this long-term vision can be stably handed to the next decade. Baillie Gifford bets on "aligned people still steering the company over the next five to ten years," and LongBio's generational succession at the R&D-strategy level does not yet have a clear answer. The second is a subtle tension between the founder's individual behavior and the narrative of "deep alignment." According to public reports, before filing (2024-12-20), chairman Liu Heng transferred 69,670 yuan of registered capital he held in LongBio Pharma to Changshu Sanyi No. 1 for 12.5534 million yuan, with payment settled only in March 2025, amounting to about 12.55 million yuan of personal cash-out before listing. The amount is not large relative to his overall shareholding, and it does not need to be exaggerated into "selling down and leaving." But within the ideal template of "founder deeply bound to the company and sacrificing the present for the long term," this pre-listing personal monetization is indeed a less clean detail worth noting. The governance section of the report also notes that certain pre-listing special rights involving Liu Heng personally were "not entirely without trace."

  Overall judgment: management's long-term view and interest alignment are qualitatively present. High ownership, a scientific leader who has bet on the same mechanism route for decades, and a long-term posture of burning cash for R&D all fit the kind of founder Baillie looks for. But "perfect alignment" is still two breaths short: who succeeds the 89-year-old core figure, and the small blemish left by the founder's pre-listing personal cash-out. For investors who truly start from a "ten-year companionship" perspective, these two points are not disqualifying, but they should be fixed items on the long-term tracking list, especially the R&D strategy succession arrangement, which will matter more than the near-term share price in determining whether this "long-termism" can be delivered.

  Jun 4, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth sustainable and not dependent on harming society or exploiting regulation?4/10

  A

  Conclusion first: if it disappeared tomorrow, customers (doctors and patients) would not miss it very much today, because LP-003 has not launched and current demand at this target is already being mostly met by substitutes. But the way it grows is healthy in itself: selling innovative biologics to meet real unmet medical needs gives it social legitimacy, and it does not rely on harming society or exploiting regulatory loopholes. This Baillie question is really testing two things: how solid real customer value is, and how firm the "social license" for growth is. LongBio's answers split in two: customer value is weak today and may only become strong later; social legitimacy is present from the start.

  First layer: the current degree of being missed is low because substitutability is too strong. As of the prospectus, LP-003 has "zero product revenue and zero sales," and commercialization has not even begun. Talking about "how much customers would miss it if it disappeared" is almost an empty set today. More importantly, it is not entering a blank market, but a field that already has mature substitutes and is becoming more crowded. On the anti-IgE path, the originator omalizumab (Novartis Xolair) was approved for CSU in China as early as 2022, entered medical insurance in 2024, and successfully renewed in 2025, with post-reimbursement per-unit cost falling below 1000 yuan. On the domestic side, CSPC's omalizumab biosimilar was approved by the NMPA for CSU in 2024, and Mabwell/Mabpharm also submitted China's first omalizumab biosimilar marketing application. The report itself also notes that China already had local Mabpharm's CMAB007 anti-IgE antibody approved for asthma in 2023. Looking further at adjacent pathways, there are dupilumab (IL-4Rα, China's autoimmune "drug king," which entered medical insurance in 2020), domestic substitutes with the same IL-4Rα mechanism, and a long list of choices. In other words, if LP-003 is absent today, doctors still have originator + multiple biosimilars + adjacent-pathway biologics in hand, and patients will not be left without treatment because it is not there. This is the root of the report's description of it as a "late-stage challenger niche player," its "medium" moat rating, and its warning that "clinical advantage ≠ commercial advantage."

  There is only one path for the degree of being missed to move from "very low" to "very high": LP-003 must be recognized by doctors and patients as preferred because of genuinely better efficacy, longer dosing interval, and better access. This is not fantasy. The CSU Phase II head-to-head data disclosed in the report are a real selling point: the 200mg Q8W group had a week 12 UAS7=0 rate of 66.7%, higher than omalizumab's 43.6%, and the company emphasizes higher affinity and a longer dosing interval. If these advantages hold in the real world, LP-003 can move from "it does not matter whether it exists" to "doctors are willing to prescribe it first and patients are willing to switch to it," and then the degree of being missed can truly be established. But the report also repeatedly warns that head-to-head superiority over omalizumab is only "a strong R&D and clinical signal." It is still far from doctor prescriptions, medical-insurance access, and scaled sales, and this step has not yet been validated in reality. So the honest statement at this stage is: potential customer value is not low, but delivered customer value is almost zero.

  Second layer: social legitimacy of growth. This is a clear plus for LongBio. Its growth model is to develop and sell innovative biologics to meet real and still far from fully met medical needs in allergic rhinitis, chronic urticaria, and PNH. LP-003 targets next-generation anti-IgE with easier dosing and better efficacy, while LP-005 targets complement-mediated diseases with high technical barriers and sharper pain points for patients lacking drugs. This type of growth does not depend on harming consumers, creating addiction or externalities, or exploiting regulatory loopholes. On the contrary, it follows the most formal path of "clinical trial → BLA → approval → medical insurance." The better the drug is and the more it sells, the greater the health benefit to society, and the company's interest and patients' interests point in the same direction. That is the "legitimacy of growth" Baillie cares most about in this question, and LongBio passes it.

  But one constraint must be stated honestly: China's medical-insurance cost control is a payment environment it cannot bypass. This is not "harming regulation," but it is a real profit ceiling. The point above about originator omalizumab entering medical insurance and seeing "per-unit cost fall below 1000 yuan" is a portrait of this mechanism. Selling innovative drugs in China often requires medical-insurance inclusion, price negotiation, and cost control before volume can scale. That means even if LP-003 is approved and clinically better, its pricing power and per-drug profit will be continuously pressured by payers. This is a rule it must actively adapt to, not a gray area it can avoid. When the report lists "clinical advantage cannot turn into payment and prescription advantage" and "the best-in-class story is pushed back to me-better but hard to monetize" as high-impact risks, it is essentially talking about this.

  One-line synthesis: if it disappeared today, customers would not miss it that much, because substitutes are in place and it has not truly entered the field. But it has chosen a legitimate, beneficial business with real demand. Growth does not rely on harming society or exploiting regulation. It simply still needs to turn "clinically better" into "customers cannot do without it" inside China's medical-insurance cost-control framework, and that step lies ahead. This also matches the report's "Watch" rating and ideal buy price of ≤HK$54: the legitimacy of a good business is present; what is missing is the moment when customer value is truly validated.

  Jun 4, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate with scale? Where is the money it earns spent?4/10

  A

  Conclusion first: looking only at the "drug" business, the unit economics of innovative biologics are actually quite attractive. Once approved and scaled, gross margin can usually reach the 85%–90% range, and unit economics get better as scale grows, which is classic operating leverage. LongBio's awkward position today is that none of its products has launched, so there is no "money earned" to spend. What it is spending is primary-market capital and this IPO's proceeds. Separating these two points is necessary to understand its cost structure.

  1. Gross margin and marginal cost: structurally, it is "high gross margin + high fixed investment + extremely low marginal cost." For antibody drugs, the major cost is not production but the upfront work: R&D, clinical trials, and the CMC (chemistry/manufacturing/quality control) system. These are basically fixed costs and do not change much with how many boxes are sold. True variable costs (drug-substance production, fill-finish, outsourced CRO/CMO) are low per unit, so the incremental gross profit from each additional unit sold is close to the selling price. That is why mature innovative-antibody companies generally have high gross margins. Keymed-B, directly comparable to LongBio, has long kept the gross margin of its commercial products above 85%, a real-world reflection of this mechanism. In other words, LongBio's cost curve is destined to be "heavy investment first, high gross margin later." Before approval, the books remain in loss; after approval, unit economics can suddenly improve.

  2. Scale becoming larger should make it "better," but with a China-specific discount. Because fixed R&D/CMC costs can be spread over more sales, in theory the more LP-003 sells, the better the unit economics. This is positive operating leverage, and it is the fundamental reason the report rates "growth" as high while rating "valuation attractiveness" as low: the market has already paid in advance for this leverage. But a discount is needed. To scale in China, innovative drugs can hardly avoid medical-insurance negotiation, and the average price cut in the 2024 national medical-insurance negotiation reached about 63%, the highest in recent years. Medical-insurance inclusion can bring volume, but after the unit price is cut sharply, actual gross margin and incremental returns will both be thinner than the "theoretical 85%–90%". So for LongBio, the real unit economics are not about "how high ex-factory gross margin is," but whether it can still generate scale effects "at post-insurance prices." This can only be verified after LP-003 truly enters commercialization and perhaps the medical-insurance catalog.

  3. "Where is the money earned spent?" It is currently spending raised capital, not profit. LongBio had a total comprehensive loss of 175.6 million yuan in 2025 and net operating cash outflow of 121 million yuan, with no profit to distribute. Its funding source is equity financing. According to the prospectus, this IPO's net proceeds are about HK$1.255 billion (the report's figure: HK$1.255bn), and use of proceeds is highly focused: about 75% goes to the R&D and commercialization of the two main lines, LP-003 and LP-005; about 13% is specifically allocated to LP-003's seasonal allergic rhinitis commercialization preparation in China (academic promotion, market research, CSO cooperation, and sales hiring); another about 10% is for working capital. The destination of this money is essentially an entry ticket to "deliver high-gross-margin unit economics": first use the proceeds to fund fixed costs (clinical wrap-up + sales organization buildout), and only after LP-003 is approved and scales can operating leverage and high incremental returns be discussed. So at this stage, judging it is not about gross margin itself, because there is no real product gross margin on the books yet. It is about whether this capital can push it from "can make drugs" to "can sell drugs."

  Jun 4, 2026
• QWhat conditions must hold simultaneously for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's share price?2/10

  A

  Conclusion first: a path to a fivefold gain over ten years exists, but it requires a long chain of conditions to all hold simultaneously. Each link alone is not a sure thing, and the joint probability becomes low when they are stacked together. Worse, entering at the IPO price of HK$96.06 means your starting point is already not cheap. It sits right against the report's neutral scenario (HK$95.7), with zero margin of safety, meaning you are betting on this fivefold after "BLA smooth progress" has already been priced in. Part of the upside has already been compressed.

  First, make the scale clear. Today's "share price" is the IPO price of HK$96.06 (the company is expected to list only on 2026-06-05, with no secondary-market price yet). Based on 74.19 million post-issuance shares, the implied market cap is about HK$7.127 billion (about 900 million dollars). For a "fivefold gain in ten years," market cap needs to reach about HK$35.6 billion, or about 4.5 billion dollars. This scale itself deserves a pause. Baillie Gifford's LTGG framework looks for "ten-year five-bagger" winners, but it prefers large-cap growth companies that already have scale and sits in highly concentrated portfolios. In other words, for LongBio to complete this fivefold path, it has to move from today's "market-cap scale far below a typical LTGG holding" into a mid-sized commercial-stage pharma company. That is not impossible, but it means the company must deliver a full transition from clinical asset to mid-sized commercial pharma, not simply compound further on top of a validated machine.

  The conditions that must hold simultaneously (missing any one link makes fivefold hard):

  • ① LP-003 rhinitis is approved on schedule and becomes a major product. This is the most fragile assumption repeatedly flagged by the report. The plan is to file the BLA before 2026Q3. If the timetable slips (supplemental materials, manufacturing consistency issues, acceptance delayed to 2027), the report's neutral scenario could "easily fall below HK$80," let alone fivefold.
  • ② Indication expansion continues to deliver. Beyond rhinitis, CSU must smoothly enter Phase III, and asthma/nasal polyps/food allergy must land one by one before a single indication can become platform-level revenue.
  • ③ The LP-005 second curve truly stands up. POC data in PNH and even complement kidney diseases must be strong enough for the market to assign a "platform premium." Otherwise valuation can only discount the single LP-003 asset, with a much lower ceiling.
  • ④ It defends share and pricing under attack from "originator + biosimilars + adjacent targets." This is now harder than when the report was written: omalizumab's originator CSU indication renewed medical-insurance access, with per-unit cost falling below 1000 yuan; multiple domestic biosimilars such as Mabpharm are already in filing/late clinical stages; and adjacent pathways such as IL-4Rα add pressure. Even if LP-003 is "head-to-head superior to omalizumab," it must earn a premium in a market where prices have already been pushed down and substitutes are entering.
  • ⑤ No major dilutive financing occurs over ten years. The company had 121 million yuan of net operating cash outflow in 2025 and zero revenue. The report estimates the post-IPO runway, even optimistically, at only 21 months (the full-proceeds "91 months" figure is static). Commercialization will burn cash to build a sales force. If the main product scales slowly, refinancing is likely, and share dilution will eat into that "fivefold" denominator.

  Are these conditions realistic? Looking at each link alone, none is absurd: the team has anti-IgE history, the CSU head-to-head data are genuinely bright, and the patient base is large. But investment returns come from joint probability. Multiplying "approval on schedule × multiple indications deliver × second curve stands up × price and share are defended × no dilution for ten years" makes the number shrink quickly. The report's own optimistic scenario is only HK$141.5 (about +47% from the IPO price), and that already fully loads "approval + uptake + LP-005 reinforcement." Fivefold requires HK$356, more than one and a half times above the report's most optimistic calculation. In other words, fivefold is not in any scenario in the report. It requires even the report's optimistic assumptions to be exceeded repeatedly and compounded for many years.

  What expectations are embedded in today's price? In one sentence: the starting point has already pulled forward a large part of "success." The IPO price is about 3.1 times higher than the 2025 Series C post-money valuation, corresponds to about 4.96 times P/B, and shows no obvious discount to 18A peers such as Qyuns that have already produced revenue and profit. The public offering's about 4470 times oversubscription reflects IPO subscription sentiment, not a fundamental safety cushion. The report classifies it as Watch and pushes the ideal buy price down to ≤HK$54 precisely because the price of 96.06 is "not a discount, but a clear premium, with zero margin of safety." So from the Baillie perspective of "finding ten-year five-baggers," the honest statement is: the path exists, but conditions are demanding and require multiple correct bets at once, while today's entry price has already paid in advance for "high probability of success". That is exactly the kind of purchase where upside is most pre-empted and tolerance for error is lowest. To bet on this fivefold, you must both believe this long chain will deliver link by link and accept a starting point with zero margin of safety.

  Jun 4, 2026
• QWhy has the market not realized all this yet? Is it because it does not understand, looks down on it, or cannot look far enough? What will become the "narrative inflection point"?3/10

  A

  First, correct the premise of this closing Baillie question: LongBio is not a name that is "ignored and undervalued." Its public offering was oversubscribed by about 4470 times, drew about HK$656.9 billion of margin financing, and received about 268,000 applications. Cornerstone investors (OrbiMed, Ruiyuan, Fullgoal, Value Partners, and others) took nearly half of the offering shares with about 87 million dollars, and the IPO price of HK$96.06 has already reached the report's neutral scenario (HK$95.7). So discussing "why the market has not realized it" for LongBio must be split into two very different layers.

  Layer 1 (short term): the market is not "looking down on it." It sees it, and it is hot. The story of anti-IgE upgrade + CSU head-to-head superiority over omalizumab + reopening of the 18A window has been understood by the market and priced enthusiastically. The report classifies the current price as "can hold" rather than a "cheap buy point," with almost no margin of safety. That itself shows the short-term narrative lacks no attention. At this layer there is no expectation gap from "not understanding/looking down on it." If anything, IPO sentiment pushing the first-day price too far is the risk. So Baillie's wording of "not understanding, looking down, or not looking far enough": the first two basically do not apply to LongBio.

  Layer 2 (long term, where the real expectation gap sits): what the market is most likely "not looking far enough" about is linearly extrapolating "clinical advantage" into "commercial success." These are exactly the two misjudgments the report repeatedly identifies: "treating clinical advantage as an automatic substitute for commercial advantage" and "equating a long runway with high returns." From attractive clinical data to prescription uptake, there is a whole gulf of BLA acceptance and approval, medical-insurance/payment access, sales organization built from zero, and doctors' prescribing habits. LongBio has zero sales and zero commercialization validation as of the prospectus. More importantly, the seasonal allergic rhinitis market it targets is not blank: Keymed's stapokibart (IL-4Rα) was approved in China in early 2025 for seasonal allergic rhinitis, is the first biologic for the indication, and has applied for 2025 medical-insurance inclusion; omalizumab and domestic substitutes are also present. When LP-003 truly launches, "best-in-class" must win share amid existing first movers and payment bargaining, not coast to victory. The market today is pricing this gulf rather optimistically. That is LongBio's real "not looking far enough."

  Positive narrative inflection point: BLA submitted on schedule before 2026Q3 and quickly accepted by the NMPA → approval → first commercial year uptake slope exceeds expectations → medical-insurance inclusion expands access → CSU advances to Phase III, and LP-005 PNH delivers strong POC to support a "platform premium." If any link is delivered, valuation can shift from a "R&D story" to a "commercialization story," and the report's optimistic scenario reaches HK$141.5. Negative narrative inflection point: BLA delay/supplemental materials, approval followed by weak uptake (share lost to IL-4Rα and others, or medical-insurance/channel friction), or flat LP-005 data. The market would then re-rate it as a "high-cash-burn clinical-stage biotech," corresponding to the report's 40%–60% maximum loss risk, the conservative scenario of HK$67.4, or even convergence toward cash value.

  Honest conclusion: LongBio's expectation gap is more likely "overpriced in the short term, needs long-term validation" than "undervalued and undiscovered." It does not lack attention. It lacks evidence that clinical advantage can become prescriptions and payment. So instead of waiting for "the market to suddenly understand someday," it is better to watch the hard inflection points: BLA acceptance, first-year uptake, and medical-insurance access. The report's message is the same: fundamentals first. Before these events land, HK$96 looks more like trading a milestone option than buying the company itself with a margin of safety.

  Jun 4, 2026

The must-ask before buying — finding a "good business," with the core question: "Who owns the moat?"

• QCan this company's business model be explained in one sentence?

  A

  In one sentence: LongBio Pharma-B is a Chinese 18A clinical-stage innovative drug company that uses its in-house antibody platforms to develop biologics for allergic and autoimmune diseases, and is now staking almost everything on whether LP-003, its next-generation anti-IgE antibody, can move from clinical data to a commercial drug prescribed by doctors. It is not yet a drug-sales company; it is an R&D company financing one lead asset toward its first paid gate.

  How will it monetize value? Strictly speaking, LongBio has no real money-making link today. The prospectus says it had no product sales revenue as of disclosure, and supports R&D, clinical trials and organization-building through equity financing and bank borrowings. In 2025 it had zero revenue, total comprehensive loss of RMB175.6 million, R&D costs of RMB126.6 million and net operating cash outflow of RMB121 million. Future revenue has two paths: LP-003 product sales after China approval, starting with seasonal allergic rhinitis and then expanding to CSU and asthma, and out-licensing, milestones or product sales from later pipelines. About 75% of net proceeds are for LP-003/LP-005 R&D and commercialization, including about 13% for LP-003 rhinitis commercialization preparation in China. The market is buying whether the lead drug can cross approval and start volume ramp-up in the next 12-18 months, not current profit.

  Where is it in the value chain? In the innovative drug chain of target discovery -> clinical development -> BLA approval -> commercialization ramp-up -> medical insurance payment, LongBio has moved beyond the earliest platform-story stage. LP-003 seasonal allergic rhinitis Phase III enrollment is complete and BLA submission to the NMPA is planned in or before 2026Q3; CSU Phase II head-to-head data also beat omalizumab. It is just before the approval -> first commercialization paid gate. But it has not become a commercial company: no revenue, no profit and no sales organization tested in the market.

  The model sounds persuasive because of mechanism credibility: the report says co-founder Sun Naichao participated in first-generation anti-IgE omalizumab development, and public information shows he was the founder of Tanox and a principal inventor of omalizumab (Xolair). LP-003 is a next-generation product aimed at improving omalizumab. But credible technical pedigree does not prove commercialization capability. That is the key untested link. The report therefore rates it Watch and stresses that HK$96.06 is a pre-listing offer-price basis that already embeds many success expectations.

  Jun 4, 2026
• QIs this market large enough? Is there still room for growth over the next 10-20 years?

  A

  Bottom line: the end market is large and still has structural growth over the next 10-20 years, but market size and LongBio's capture are separate questions. For a company valued at about HK$7.1 billion with zero sales, a high ceiling is not a margin of safety; the bottleneck is whether it can lift penetration.

  LP-003's allergy market is the strongest support. China is the world's largest allergic rhinitis patient pool: more than 200 million people are affected, with self-reported prevalence rising from 11.1% in 2005 to 17.6% in 2011, and adult prevalence in multiple cities is 9.6%-23.9%. CSU prevalence in China is about 1.29%, implying tens of millions of patients and a clearer anti-IgE payment path. Omalizumab (Xolair) had about USD3.89 billion global sales in 2023; the omalizumab market is expected to grow from about USD2.5 billion in 2025 to USD4.2 billion in 2033, about 7% CAGR; and global CSU is roughly about USD1.5-2.0 billion in 2023 rising to about USD2.6-5.0 billion in 2031-2032. The track is large and expanding.

  The more important fact is China's very low penetration. China's omalizumab market was only about RMB41.61 million in 2020, up +281% YoY, tiny against 200 million rhinitis patients and tens of millions of CSU patients. About one-third of Chinese CSU patients remain resistant to quadruple-dose second-generation antihistamines. LongBio is betting that biologics in Chinese allergy can move from 1% penetration toward 10%. The runway is long, but education and reimbursement make the ramp uncertain.

  LP-005 for PNH follows another logic: large value, few patients. Global PNH treatment market was about USD5.75 billion in 2024 and is expected to reach about USD9.96 billion in 2030, about 9.6% CAGR, with Asia-Pacific around 10.3%. It adds second-curve and high-price optionality, but remains too early to support valuation independently.

  Overall, the market is large and the 10-20 year growth space exists. The report's caution is not market size, but valuation: Watch rating, ideal buy <=HK$54 and neutral scenario HK$95.7 imply the offer price already includes LP-003 approval and penetration. A high ceiling supports the LP-003 bull case but cannot itself be a current-price margin of safety.

  Jun 4, 2026
• QIs its moat deep enough? Is it hard for competitors to copy?

  A

  Conclusion: not deep enough. LongBio has a prototype technical barrier, not a proven commercial moat. The report's medium moat rating is reasonable, and competition may deserve an even more conservative view.

  The report's moat has three layers: people and know-how, because Sun Naichao worked on first-generation anti-IgE omalizumab at Tanox; platform and repeated druggability, because two antibody platforms have produced multiple pipelines; and clinical path selection, moving from seasonal allergic rhinitis to CSU, asthma, nasal polyps and food allergy. These are starting advantages, not moats. The report is right that 860-fold affinity and 30-fold blocking activity do not automatically equal a moat. They must pass clinical efficacy, reimbursement, prescription habits, supply and commercial execution. Technical parameters are not prescription share.

  Competition is crowded. Originator omalizumab was approved in China in August 2017. Mabpharm CMAB007 was approved in May 2023 as China's first omalizumab biosimilar, and CSPC's Enyitan won indications in 2024-2025. Next-generation anti-IgE is not exclusive either: Novartis has a next-generation IgE antibody with FDA Breakthrough Therapy designation, and Innovent's IBI3002 and other IgE pipelines have entered clinical trials. Even with CSU Phase II 200mg Q8W week 12 UAS7=0 of 66.7% vs omalizumab 43.6%, LP-003 faces originators, biosimilars and next-generation products.

  So the moat question is the same as the Watch rating. LongBio has a real starting lead, but it is concentrated in LP-003 and can shrink if rhinitis BLA is delayed. The report rates moat medium, valuation attractiveness low and ideal buy <=HK$54 because investors are paying for a clinical milestone, not an already dug moat. Watch whether clinical lead becomes prescriptions and payment, especially commercial team build-out and first-year sales performance.

  Jun 4, 2026
• QWhere does its growth come from? (industry growth / market share / pricing / capital allocation)

  A

  Conclusion: for a zero-revenue, zero-profit clinical biotech, growth means where the first revenue appears and how it expands. In the Buffett dimensions, only parts of industry growth and market share support the story: the allergy track is large and LP-003 rhinitis first-launch volume is the only near-term real driver. Pricing is basically absent, and capital allocation is still a concentrated bet on one main asset.

  Industry growth: China has about 240 million allergic rhinitis patients, SAR is about 20%, and China's anti-allergy market reached about RMB30.9 billion in 2023. Guidelines already include anti-IgE, so education starts with a base. But a long track does not equal high return; product differentiation, payment and channel execution decide returns.

  Market share: all growth starts from zero share. LP-003 must take prescriptions from existing therapies and entrants. Rhinitis Phase III enrollment is complete and BLA is planned before 2026Q3, making it the only near-term volume driver. CSU and asthma are still Phase II; nasal polyps and food allergy are still mainly expansion narrative. Competitors are already there: Keymed's stapokibart (IL-4Rα) has been approved for seasonal allergic rhinitis, alongside omalizumab and local substitutes. Market share is the real driver, but hard to win.

  Pricing: LongBio has no marketed product, so price increases cannot drive growth. LP-003 may have initial launch pricing if it proves better and longer-acting, but that is not recurring pricing power and must pass reimbursement or self-pay affordability. The report lists failure to turn clinical advantage into payment and prescription advantage as a high-impact risk. Pricing is nearly empty.

  Capital allocation: IPO net proceeds of about HK$1.255 billion are concentrated, with about 75% for LP-003/LP-005 R&D and commercialization and about 13% for LP-003 rhinitis commercialization preparation in China. This can fund the move from making drugs to selling drugs, but it is not yet proven ROIC-based capital allocation. It is a concentrated bet, not a compounding discipline.

  Summary: LongBio's growth story is industry size + LP-003 rhinitis volume + later CSU/asthma signals + LP-005 optionality. Because everything depends on the 2026Q3 BLA path, the report calls value highly concentrated with weak safety margin, rates it Watch and sets ideal buy <=HK$54.

  Jun 4, 2026
• QIs management reliable? Is it honest and rational?

  A

  Bottom line: management's professional credibility is a strength, and the report's medium-high score is defensible. But on honesty and rationality, two details deserve attention: succession risk around an 89-year-old core founder and one pre-filing personal cash-out by the chairman.

  The credible side has substance. Sun Naichao, described as responsible for R&D strategy, is the 89-year-old pharmaceutical elder who co-founded Tanox in Houston in 1986 and was one of the principal inventors of omalizumab (Xolair). LP-003 is therefore a technical continuation led by an original inventor, not a borrowed concept. Chairman Liu Heng's background also checks out: Ryzneuta, which he helped develop, received US FDA approval and had a global program with more than 1200 subjects. Liu Heng and concert parties still control about 35.7% after issuance, so alignment is material.

  The open questions are also real. First is succession risk: according to public reports, Sun has been a director since 2020 and became executive director in August 2025 to oversee overall R&D strategy; he is 89. A company whose anti-IgE know-how is tied to one 89-year-old figure should have a clear succession plan. Second is the chairman's pre-filing cash-out: Rui Finance reported that Liu Heng transferred RMB69,670 registered capital in December 2024 for RMB12.5534 million, settled in March 2025. This is not rare in pre-IPO restructuring, but it creates tension with the deep-founder-alignment narrative. The report also notes that some founder-level special rights are not entirely trace-free.

  Overall: drug-development ability and historical credibility are genuine strengths, supporting medium-high. But succession uncertainty, pre-filing monetization and residual special rights leave watch items. They do not negate management, but they make post-listing proof important, especially whether the 13% commercialization budget becomes a real sales and access organization.

  Jun 4, 2026
• QWill it become stronger 10 years from now? (Will users, profits and brand strengthen?)

  A

  Conclusion: whether LongBio is stronger in 10 years depends not on lab metrics such as 860-fold affinity, but on whether it can pass the narrow path of approval, ramp-up, payment and share defense. Upside means moving from an R&D story into a commercial drug company with cash flow, brand and platform. Downside means returning to a high-cash-burn clinical biotech if any key link fails.

  The upside path needs three things. First, LP-003 rhinitis BLA is submitted before 2026Q3 and approved; its differentiation, including 100mg achieving comparable efficacy at about one-third of omalizumab dose and Q4W dosing across the allergy season, plus CSU Phase II 200mg Q8W week 12 UAS7=0 of 66.7% vs omalizumab 43.6%, must become prescriptions and adherence. Second, LP-005 must stand up as a second curve. Third, the platform must expand indications to CSU, asthma, nasal polyps and food allergy. If these happen, users, profits and brand strengthen, matching the report's optimistic HK$141.5 scenario. The track is large: China has about 240-260 million allergic rhinitis patients and a 2023 medication market of about RMB41.6 billion moving toward RMB50 billion by 2028; CSU is expected to grow about 16% annually to about RMB41.7 billion by 2030.

  The downside is equally concrete. LP-003's first-launch story in seasonal allergic rhinitis is not a blank market: Keymed's stapokibart (IL-4Rα) was approved in February 2025 for seasonal allergic rhinitis and entered the 2025 national reimbursement list, effective January 1, 2026. Dupilumab China sales grew about 33% in 2024 and exceeded RMB2.5 billion, omalizumab has domestic copies already marketed, and multiple anti-IgE antibodies are in clinical development with some in Phase III and earliest approvals around 2026. LP-005 also faces a crowded complement market where 6 C5 drugs have been approved globally and domestic players are clustering.

  My view: LongBio has a path to be stronger, but the conditions are demanding. If BLA is delayed, ramp is slow, or reimbursement/share is squeezed, the report's 40%-60% maximum downside and HK$67.4 conservative scenario become relevant. Watch BLA submission/acceptance, CSU Phase III, LP-005 data and whether the 13% commercialization budget becomes sales and access capability.

  Jun 4, 2026
• QIs the current price reasonable? Is there a margin of safety?

  A

  Conclusion: it is not cheap, and the margin of safety is basically zero. Because LongBio had not formally listed as of the report, with listing planned for June 5, 2026, the current price means the offer price HK$96.06. The report says this is a clear premium to the conservative intrinsic value of HK$67.4 and almost exactly the neutral scenario of HK$95.7.

  Why expensive? First, the implied market cap of about HK$7.127 billion is about 3.1 times the May 2025 Series C post-money valuation of RMB2.0078 billion. Second, the market cap overlaps Qyuns Therapeutics-B, which had more than RMB800 million revenue and profit in 2025, while LongBio has zero revenue and zero profit. Third, pro forma tangible net assets of HK$19.37 per share imply about 4.96 times P/B, not low for a clinical-stage biotech.

  Why was demand hot? Public offering oversubscription of about 4470 times and about HK$656.9 billion involved reflect extreme IPO sentiment. Cornerstones took US$87.0m, about 49.96% of the offering. But oversubscription is not fundamental safety; value still depends on LP-003 approval and commercialization.

  Entry point: the report's ideal buy is <=HK$54, using a 20% margin under conservative HK$67.4. HK$81-110 is a holdable range around neutral HK$95.7, while >=HK$156 is clearly overvalued. HK$96.06 is holdable but not cheap. If the 2026Q3 BLA expectation is cut, neutral value can fall below HK$80, and maximum downside is 40%-60%. This is a clinical milestone trade, not buying the company with safety margin.

  Jun 4, 2026

Finding the "value-capture point" — the core question: "Which link will the biggest future profits bottleneck at?"

• QWhere does this company sit in the industry value chain?

  A

  Conclusion: LongBio is an in-house antibody originator and clinical asset holder in the innovative drug value chain, positioned at the critical late-stage clinical -> approval and first commercialization inflection point. It is not a CXO, tool provider or platform-service seller; it owns drug assets it invented and advanced, and plans to sell itself or through channels.

  In the chain of target/antibody discovery -> clinical development -> BLA approval -> commercialization ramp-up -> reimbursement/payment, LongBio spans discovery to late-stage clinical development and is at the approval gate. It has high-affinity antibody discovery and bifunctional antibody platforms. LP-003 seasonal allergic rhinitis has completed Phase III enrollment in China and plans BLA submission in or before 2026Q3; LP-005 is in China PNH Phase II. But it has not entered commercialization/payment: zero products, zero sales, no tested prescribing, reimbursement or sales organization.

  Its originator identity is real. Co-founder Sun Naichao co-founded Tanox and co-invented omalizumab (Xolair). LP-003 is a next-generation anti-IgE antibody led by an omalizumab inventor. Value capture depends on proprietary IP and clinical data differentiation, such as CSU Phase II 200mg Q8W week 12 UAS7=0 of 66.7% vs omalizumab 43.6%, not on service fees or capacity.

  Upstream, it relies on R&D and outsourced CRO/CMO while keeping target selection, molecule design and clinical strategy. Downstream, hospitals, physicians and payers decide whether value is realized. The report's neutral HK$95.7 almost equals the HK$96.06 offer price, meaning the market has priced the late-stage originator position on the assumption that BLA broadly proceeds on schedule.

  Jun 4, 2026
• QWhat exactly does it sell? What will actually make money?

  A

  Conclusion: today LongBio sells expectations, not drugs. As of the prospectus it had zero product sales revenue and zero profit, with 2025 total comprehensive loss of RMB175.6 million and R&D costs of RMB126.6 million. It sells investors the expectation that LP-003 can be approved and ramped, plus long-term antibody platform optionality.

  What it sells now is a three-layer story: LP-003's first commercial shot in China's large allergy market; LP-003's head-to-head advantage over omalizumab as best-in-class, with CSU Phase II 200mg Q8W week 12 UAS7=0 of 66.7% vs 43.6%; and Hong Kong 18A IPO window recovery. Buying at HK$96.06, implied market cap about HK$7.127 billion, means buying the probability that these come true.

  What will actually make money has two paths: LP-003 product sales after China approval, first seasonal allergic rhinitis and then CSU, asthma, nasal polyps and food allergy; and future pipeline licensing and milestones. The company is advancing US IND and overseas bridging for LP-003/LP-005, but no license or milestone revenue has landed. Compared with Keymed and Qyuns, LongBio's income path is still future tense.

  The gap is 100% narrative and 0% cash flow today. Neutral value HK$95.7 nearly equals the offer price, so BLA progression is already priced. If LP-003 rhinitis filing, approval or ramp slips, the report expects 40%-60% maximum downside. The key is the first real drug sales revenue from LP-003, not how much story is sold today.

  Jun 4, 2026
• QWhy would customers buy it? Who provides these capabilities?

  A

  Conclusion: only after LP-003 is approved and accepted by payers can we discuss customers buying it. As of June 2026, with listing expected on June 5, it had no approved product and no sold dose; all customer logic is hypothetical. Buyers are prescribing doctors, patients who use and pay, and payers deciding reimbursement.

  Doctors and patients would choose it for three relative advantages. First, efficacy: CSU Phase II 200mg Q8W week 12 UAS7=0 was 66.7% vs omalizumab 43.6%, though reports note the primary endpoint p value versus omalizumab was about 0.0501, so Phase III/real-world proof is needed. Second, convenience: LP-003's half-life of about 45-76 days is longer than omalizumab's 24-26 days. Third, access: omalizumab is already reimbursed for CSU with out-of-pocket cost below RMB1000 per dose, and CSPC and others are pressuring price. LP-003 must prove better efficacy, longer interval and get reimbursement quickly.

  Capabilities come from in-house and external sources. LongBio owns the high-affinity antibody discovery platform and bifunctional antibody platform, which generated the 860-fold affinity and 30-fold blocking activity claims. It also has anti-IgE know-how from Sun Naichao, who co-founded Tanox and whose system produced omalizumab (Xolair) in 2003. Clinical data, including CSU head-to-head and rhinitis Phase III enrollment, are its evidence. Production and manufacturing are mainly outsourced to CRO/CMO partners.

  So customers may buy LP-003 for platform-derived differentiation, Sun's anti-IgE heritage and clinical data, while manufacturing is externally supported. But this remains unvalidated until BLA approval, reimbursement and physician acceptance close the loop.

  Jun 4, 2026
• QWhere will demand growth come from over the next 3-5 years?

  A

  Conclusion: demand growth over 3-5 years comes mainly from biologics upgrading traditional therapies, anti-IgE indication expansion, especially rhinitis, and improved diagnosis/payment, not from new patient growth alone. This is industry demand; LongBio must still convert it through LP-003 BLA, prescriptions and reimbursement.

  First, anti-IgE is ramping and rhinitis remains under-opened. China's anti-IgE antibody market is expected to grow from about RMB2.0 billion in 2024 to about RMB12.1 billion in 2030, about 32.5% CAGR. Omalizumab in China is approved only for allergic asthma and CSU, not seasonal allergic rhinitis, which is LP-003's planned first-launch position before 2026Q3 BLA.

  Second, biologics can upgrade from antihistamines/steroids. China's CSU market rose from RMB12.4 billion in 2019 to about RMB16.9 billion in 2024 and may reach about RMB41.7 billion in 2030, about 16.2% CAGR. Allergic rhinitis has about 200 million to 250 million patients, and about 62% of moderate-to-severe patients remain uncontrolled despite regular nasal steroids and antihistamines. Keymed's stapokibart approval in February 2025 shows biologics for rhinitis are being accepted, while also proving competition.

  Third, diagnosis and payment amplify demand. A national survey showed allergic rhinitis weighted prevalence of about 8.1%, with only about 23.7% aware of diagnosis. Omalizumab reimbursement for CSU, with cost-effectiveness studies after reimbursement, shows payment can improve access and volume.

  LP-005/PNH is different. PNH incidence is about 1.3 per million, and demand growth comes from diagnosis and targeted complement therapy penetration, not patient count. LP-005 is still PNH Phase II, so it is a second curve, not the current demand driver.

  For LongBio, these are tailwinds, not guarantees. It has zero product sales, zero commercialization validation and value concentrated in LP-003. The HK$96.06 offer price already prices BLA progress near the neutral HK$95.7 scenario. Demand growth must still become prescriptions and payment in a market with omalizumab, local substitutes and IL-4Rα competitors.

  Jun 4, 2026
• QIf industry demand grows 5 times, which link will become scarce first?

  A

  Conclusion: if Chinese allergy/complement biologics demand grows 5 times, the first scarce links will not be capacity or salespeople, but differentiated products clinically recognized by payers, and reimbursement/payment budget for high-priced biologics. Product quality decides entry; payment budget decides volume.

  Antibody CMC and fill-finish are basically not scarce. Monoclonal antibody production is mature, and China has CDMO excess capacity. Frost & Sullivan's 2025 CDMO blue paper notes overcapacity pressure, and TOT BIOPHARM alone has 300,000L bulk antibody and 20 million finished-dose annual capacity. Demand can be met through expansion and outsourcing.

  Sales and physician education will be tight but scalable. Anti-IgE is already in Chinese guidelines for allergic rhinitis and CSU. Sales teams and CSO cooperation can be built with money in 1-2 years; LongBio allocated about 13% of proceeds for this. It is execution difficulty, not structural shortage.

  Payment budget is the hard back-end bottleneck. China's basic medical insurance pool is about RMB3 trillion, while reimbursement entry often requires about 60% average price cuts and patients may still pay nearly 50% of actual costs. The Commercial Health Insurance Innovative Drug List was created to relieve this payment bottleneck. Money is more likely to run out before capacity.

  The deepest shortage is payer-recognized differentiated products. China has many me-too drugs, but homogeneous PD-1 and single-target competition shows me-too will fail under reimbursement cost control. The scarce supply is products that prove better efficacy or longer dosing in head-to-head and real-world data and deserve payer budget. The profit bottleneck is differentiated product x payment access.

  Jun 4, 2026
• QIs this company that first-scarce link?

  A

  Conclusion: probably not. Even if demand grows 5 times, LongBio is unlikely to be the first-scarce, highest-bargaining-power bottleneck. It is more like one of many suppliers in an already crowded anti-IgE market.

  LP-003's anti-IgE mechanism is not exclusive. Omalizumab is already in China; Mabpharm CMAB007/Omalishu was approved for allergic asthma in May 2023; CSPC and others are lining up. Adjacent mechanisms also compete: Keymed stapokibart (IL-4Rα) is already approved for seasonal allergic rhinitis, directly hitting LP-003's first intended indication. Patients and doctors have alternatives, and antibody developers/capacity are not scarce.

  The truly scarce items are differentiated efficacy recognized by payers and reimbursement access. LP-003's CSU Phase II 200mg Q8W week 12 UAS7=0 of 66.7% vs omalizumab 43.6% is a strong signal, but the report stresses that clinical advantage does not automatically become commercial advantage. LP-003 has not yet filed BLA and its commercial team is untested.

  LongBio can become scarce only if LP-003's best-in-class case is validated by real-world data and payment, turning me-better into me-best. Before that, it is a promising but unproven supplier. This explains why the report treats HK$96.06 as a clinical milestone trade, not a safety-margin purchase, and sets ideal buy <=HK$54.

  Jun 4, 2026
• QWhat would happen to the value chain if this company shut down tomorrow?

  A

  Bottom line: as of "today," if LongBio shut down tomorrow, China's allergy and complement biologics value chain would barely feel it. That is exactly the point: its current indispensability is low, and its value capture has not truly been established. The reason is straightforward. LongBio is expected to list only on 2026-06-05; as of publication it has zero product revenue and zero commercialization validation. LP-003 is still waiting for BLA submission (planned before 2026Q3), and LP-005 is still in Phase II for PNH. If a company that has "not sold a single drug to a patient" disappears, patients, doctors, and payers will not immediately be missing anything.

  The work it wants to do is already being covered by existing alternatives. In the anti-IgE/allergy field where LP-003 is focused, the originator omalizumab (Novartis Xolair) has long been approved in China for chronic spontaneous urticaria and allergic asthma, and omalizumab biosimilars from CSPC, Mabpharm, and others were also approved one after another in 2024–2025. In adjacent mechanisms, Keymed's stapokibart (IL-4Rα) also won approval for seasonal allergic rhinitis in February 2025, and IL-4/13-pathway biologics such as dupilumab are also in use. In other words, LongBio is not trying to enter a white-space market. It is trying to win prescription share away from existing therapies, which the report also makes explicit. If it exited now, patients in these indications would still have drugs available, and the value chain would not be missing a link. The complement field where LP-005 sits is narrower and has fewer players, but LP-005 itself remains in early clinical development, so there is no basis for saying the field is "supported" by it.

  The key is to separate "minimal impact now" from "impact could become larger if it succeeds later." This counterfactual question tests the strength of value capture. Indispensability is not about whether a company "wants" to be important, but how much of the value chain it has "already" locked up. LongBio currently locks up approximately 0 share, so the shutdown impact is approximately 0. The real turning point would come only after LP-003 passes approval, wins substantial prescriptions on the basis of the real differentiation repeatedly emphasized in the report, such as the CSU Phase II head-to-head data where the 200mg Q8W group reached a week 12 UAS7=0 rate of 66.7% vs omalizumab's 43.6%, and builds a sales and access system. At that point, if it shut down, a group of patients using LP-003 would need to switch therapy and a piece of market share it had captured would be reshuffled. Only then would the "shutdown impact" move from negligible today to meaningful.

  So the answer to this question is essentially the other side of the same coin as the report's "Watch" rating and the fact that the IPO price of HK$96.06 already prices in a fair amount of success expectation: what investors are paying for now is almost entirely the expectation that "it can become indispensable in the future," not the fact that "it is already indispensable today." Whether that expectation can be delivered still depends on LP-003's rhinitis BLA submission and approval, and on real post-approval uptake, rather than on its current presence in the value chain.

  Jun 4, 2026
• QCan customers replace it? How long would that take? How many years would it take for a new competitor to enter?

  A

  Two-sided conclusion first: customers (doctors, patients, and payers) can replace it almost at any time, with very low switching friction; meanwhile, a "brand-new competitor" usually needs more than 5–8 years to move from clinical development to approval, which sounds like a deep moat. The bad news is that real new anti-IgE rivals are already in the clinic, not waiting to arrive years later. Taken together, these two facts line up with the report's "Watch" rating and its view that the "IPO price of HK$96.06 already prices in a fair amount of success expectation": LongBio has not locked anyone in yet.

  Start with how easy it is to replace it: very easy. Even if LP-003 successfully submits its BLA in 2026Q3 and is later approved, it will not enter a blank market. It will enter a field already crowded with several options, where doctors face almost no switching cost in prescriptions. The originator omalizumab (Novartis Xolair) has long been approved in China for allergic asthma and chronic spontaneous urticaria. On the domestic side, Mabpharm's CMAB007 (for allergic asthma) is China's first approved omalizumab biosimilar, while CSPC's omalizumab biosimilar was approved for chronic spontaneous urticaria. In adjacent mechanisms, Keymed's stapokibart (China's first IL-4Rα monoclonal antibody) won a seasonal allergic rhinitis indication in February 2025, and Regeneron's dupilumab, along with the IL-4/13 pathway, can also divert the same patient pool. In other words, doctors treating these indications already hold multiple cards: "originator + biosimilars + adjacent targets." For LP-003 to win and defend prescriptions, it cannot rely on patients having "no choice"; it must rely on real efficacy, dosing convenience, and reimbursement. The CSU Phase II head-to-head advantage repeatedly emphasized by the report (200mg Q8W group week 12 UAS7=0 rate of 66.7% vs omalizumab's 43.6%) is meant to create that "hard to give up" stickiness, but that stickiness can only be discussed after launch and uptake. Today it is still zero.

  Now look at how many years it takes for new competitors to enter: 5–8 years on the surface, but actual rivals are already on the road. A brand-new antibody typically needs 5–8 years or even longer from first-in-human clinical study to NMPA approval. Looking only at that, LP-003 seems to have a meaningful lead window. But anti-IgE/allergy is a recognized large-indication field. Players are not going to appear only years from now; they are already in clinical development, some even near later stages. For example, Jemincare's long-acting anti-IgE antibody JYB1904 (licensed overseas to RAPT for more than 700 million dollars and renamed RPT904) is in Phase II in China for asthma and CSU, and the company expects CSU Phase II data to read out in the first half of 2026. Its selling point is also a "longer half-life and deeper, more durable suppression of free IgE," directly targeting the same "stronger and longer-acting" narrative as LP-003. Put differently, even if LP-003 is approved first, it is unlikely to enjoy the window alone for long. Within a few years, it will probably face direct competition from same-generation long-acting anti-IgE products.

  Putting both sides together, this question tests the durability of value capture. The answer is negative, though it should be read by stage: today's LongBio has low switching costs (customers can replace it at any time), and entry barriers are not very effective against "rivals already in clinical development" (new rivals are already on the road). So it has not truly locked in any stakeholder yet. This is one root reason the report assigns a "Watch" rating, pushes the ideal buy price down to ≤HK$54, and points out that the IPO price is at a clear premium to the conservative scenario of HK$67.4. To reverse this conclusion, LP-003 must pass approval and then use efficacy + long-acting dosing + medical insurance inclusion to turn "can switch at any time" into "switching is not worth it," while winning enough prescriptions and access before same-generation rivals such as Jemincare are approved. The metrics to watch remain BLA submission and acceptance, plus the real post-approval uptake curve, rather than its current paper lead.

  Jun 4, 2026
• QCan supply expand? What conditions are required?

  A

  Conclusion first: the question of whether anti-IgE/allergy biologics supply "can expand" has to be split into two layers. At the industry level, "capacity" can expand almost at any time and is not scarce at all. What is genuinely scarce and genuinely hard to expand is high-quality supply of "differentiated good drugs + recognition and payment from medical insurance." This matters directly for LongBio because it shows that simply making a drug and piling up capacity does not create a moat. The dividing line is whether clinical advantage can become real supply that is "prescribed and reimbursed." This is also the underlying logic behind the report's description of LongBio as a "late-stage biotech company undergoing valuation reset" and its decision to assign only a "Watch" rating.

  At the industry level, antibody-drug capacity is actually easy to expand. That is bad news, but it is also the fact. Monoclonal antibodies are not a scarce process. If a company is willing to spend on CMC and CDMO, capacity can be built fairly quickly. Domestic leader WuXi Biologics has planned total capacity of more than 500,000 liters, and its continuous bioprocessing platform can use a 1000-liter reactor to approach 800 kilograms of annual monoclonal-antibody capacity, equivalent to a conventional 10,000-liter-scale reactor. The industry has even seen discussion of "capacity surplus and pressure on leaders" in large-molecule CDMO. In other words, "being able to manufacture it" is almost not the constraint. The real bottleneck sits further downstream: first, the product itself must show clinical differentiation that doctors will recognize (LongBio's pitch is LP-003's upgrade over omalizumab in affinity, blocking activity, and dosing interval, plus CSU Phase II data where the 200mg Q8W group achieved a week 12 UAS7=0 rate of 66.7%, better than omalizumab's 43.6%); second, it must obtain medical-insurance payment, which is a hard constraint in China. Although the 2025 national medical-insurance negotiation included 114 new drugs and raised the negotiation success rate for innovative drugs to about 88%, the average price cut was as high as about 63%. "Getting into the catalog" and "selling at a high price" are two different things. So supply scarcity does not lie in "capacity," but in high-quality supply that is "recognized + paid for," and that opening remains narrow.

  At the company level, LongBio needs four conditions to come together before its own "supply" can truly expand, and none has been delivered yet. First, BLA approval: LP-003's Phase III seasonal allergic rhinitis trial has completed enrollment, and the company plans to submit the BLA to the NMPA before the third quarter of 2026. This is the first gate from "clinical asset" to "sellable supply." Second, CMC scale-up and stable supply: moving from clinical batches to commercial batches requires process consistency and supply stability that can withstand regulatory and market scrutiny. Third, building a commercialization sales team: the report discloses that the company allocated about 13% of net proceeds specifically to LP-003's rhinitis commercialization preparation in China (academic promotion, market research, CSO cooperation, and sales hiring). This is the critical jump from "can make drugs" to "can sell drugs." Fourth, a cash runway that can carry the uptake phase: the report's base is that, assuming cash burn at 1.3 times the 2025 level, cash plus financial assets can support more than 13 months; including 10% of IPO net proceeds extends that to about 21 months; including all net proceeds would theoretically cover about 91 months. That 91 months is static and should not be read as meaning no refinancing will be needed, but it does show that if the IPO is completed successfully, short-term liquidity is not the most dangerous line.

  What does this mean for LongBio? It means the ease of expanding supply is itself a warning: capacity is not a barrier, and any would-be entrant can use a CDMO to manufacture an anti-IgE antibody. Whether LongBio can establish itself in this field does not depend on how much drug it can manufacture. It depends on whether it can cross the narrow path of "approval, uptake, medical-insurance payment, and share defense" earlier and better than others. The point repeatedly stressed by the report holds again here: clinical advantage does not automatically equal commercial advantage. China's allergy biologics market already has the omalizumab originator and domestic substitutes, Mabpharm's CMAB007, and other existing players. New-generation products are fighting for doctors' prescription share, not entering a blank market. So the indicators worth watching are not "capacity news," but the hard metrics identified by the report: whether the rhinitis BLA is submitted and accepted on schedule, whether the commercialization team and hospital access are implemented, and whether the medical-insurance payment path can be opened. If those move well, LongBio's "high-quality supply" can truly expand. Otherwise, even large theoretical capacity is just silent fixed cost.

  Jun 4, 2026
• QWhich part of the value chain will profits ultimately flow to?

  A

  Conclusion first: in the innovative-drug value chain, profits ultimately flow to the originator layer that "holds differentiated products, has pricing power, and obtains payment access." That is exactly the money LongBio wants to earn, not CRO/CMO processing fees or distribution-channel spreads. But it is equally important to be honest: whether it can capture that originator profit, and how much, has not been delivered at all yet, and it will probably be meaningfully thinned by the two forces of "China medical-insurance cost control + same-class competition." This is the root of the report's "Watch" rating and its conclusion that "value capture is not outstanding."

  First, clarify how profits are distributed along this chain. The innovative-drug value chain roughly runs from target and antibody discovery → clinical advancement → BLA approval → commercial uptake → medical insurance/payment. Clinical outsourcing (CRO) and commercial manufacturing (CMO/CDMO) in the middle earn relatively stable but capped processing/service fees. Channels (distribution, pharmacies, CSO) earn distribution spreads. Neither segment can easily capture the product's excess return. The real lion's share goes to the originator holder that owns the patent, creates efficacy differentiation, and turns that differentiation into prescriptions and payment. LongBio's entire playbook, including its self-developed antibody platform, pushing LP-003 all the way to BLA, putting about 75% of IPO net proceeds into LP-003/LP-005 R&D and commercialization, and allocating another about 13% specifically to rhinitis commercialization preparation, is aimed at occupying the originator slot and capturing product-side profit. So the answer to "which part of the chain is it in" is clear: it wants to be the originator layer. The only question is who is already sharing the profit in that slot, and how much will be left for it.

  Why will its capture be meaningfully thinned? This is where the Serenity question really lands, and there are two forces. The first is medical-insurance cost control. Once an innovative drug in China enters national medical insurance and scales, unit profit at the drug level is continuously pressured downward. Historically, successfully negotiated drugs have seen average price cuts of about 50%~60%, with some products cut by 80%~90%. The newly added "commercial-insurance innovative drug catalog" in 2025 offers another payment route, but estimated suggested price-cut ranges are also 15%~50%. In other words, even if LP-003 is approved and scales, gaining medical-insurance access and expanding the patient base will almost certainly require giving up a meaningful portion of unit-price profit. Volume rises, margins fall. That is the typical way the "payment" link takes a slice from originator profit. The second force is same-class competition. The "first launch" that LP-003 is proud of is not truly white space in its most important seasonal allergic rhinitis segment: Keymed's stapokibart (IL-4Rα) was approved for seasonal allergic rhinitis in February 2025, and all 3 indications, including seasonal allergic rhinitis, were included in the 2025 national medical-insurance catalog, effective 2026-01-01, with annual out-of-pocket cost after assistance of about 31,000 yuan. Add the omalizumab originator, dupilumab already in medical insurance (reduced after renewal to about 1508 yuan/300mg and 1105.6 yuan/200mg), and CSPC's domestic copy, and all are competing for this prescription pool. A biologic with a different mechanism but the same rhinitis use has already been approved before LongBio and obtained medical-insurance access first. That means when LongBio enters, the profit in the originator slot has already been shared by several first movers, and neither pricing power nor payment access will be uniquely its own.

  So my honest view is that LongBio sits in a position with a chance to capture originator profit, but with that profit thinned by both payment and competition. On the upside, if LP-003 truly becomes best-in-class (its selling points are the CSU Phase II head-to-head data where the 200mg Q8W group had a week 12 UAS7=0 rate of 66.7%, better than omalizumab's 43.6%, plus longer-acting dosing) and successfully enters medical insurance and scales, it can indeed capture the richest profit layer in the originator slot, corresponding to the report's optimistic scenario of HK$141.5. But if the BLA is delayed, post-approval uptake is slow, medical-insurance negotiation cuts price hard, or first movers hold onto share, the profit it captures will be heavily discounted, corresponding to the report's conservative scenario of HK$67.4 and maximum loss risk of 40%~60%. Given the IPO price of HK$96.06 and the implied market cap of about HK$7.127 billion already pricing in "BLA progressing on schedule," with no obvious discount to peers such as Qyuns that already have licensing income, the market is currently assigning optimistic pricing that assumes "originator profit can probably be captured." The real capture ability still has to be proven by hard milestones: rhinitis BLA acceptance, medical-insurance payment path, and first-year uptake curve. In one sentence: LongBio is aiming at the thickest profit slot in the chain, but it has to fight for it under the double squeeze of medical-insurance price pressure and same-class competition. Whether it can defend that slot, and how much, has not yet been decided by any delivered fact. That is what the report means when it repeatedly says "value capture is not outstanding."

  Jun 4, 2026
• QHow much profit elasticity does the company have? If revenue grows by 10%, how much would profit grow?

  A

  Conclusion first: today it is not possible to discuss LongBio's profit elasticity using "if revenue rises 10%, how much does profit rise", because both revenue and profit are currently zero. With a zero base, the elasticity formula simply cannot stand. A more accurate description is that LongBio's current operating leverage is "running in reverse". The report says this plainly in the business-model section: for this type of company, pre-approval operating leverage is basically reverse leverage. Revenue has not started, while costs run ahead. Once the main asset goes off track, expenses are hard to cut immediately. So the real profit elasticity is not present now; it sits beyond the point where the company crosses breakeven. Separating these two stages avoids being misled by an attractive but distorted elasticity number.

  Stage 1: the current "reverse leverage" is real cash burn. LongBio had zero product sales revenue and zero profit in both 2024 and 2025. In 2025, total comprehensive loss was RMB 175.6 million, R&D cost was RMB 126.6 million, and net cash outflow from operating activities was RMB 121 million (RMB 104.1 million in 2024, still expanding). Its fixed costs are R&D staff, clinical project management, CMC, and the registration system. Variable costs are mainly clinical trials, outsourced CRO/CMO, and future commercialization preparation. These costs continue to flow out with no revenue coming in. In other words, giving it "10% more revenue" at this stage is a false premise. The income statement's sensitivity to revenue currently shows up as losses coming first and runway being consumed, rather than "profit jumping when revenue moves." This is why the report describes it as a typical "high-cash-burn clinical-stage biotech," one fundamental reason for the "Watch" rating and zero margin of safety.

  Stage 2: true high elasticity will only be delivered after LP-003 crosses the breakeven inflection point, and it would then be very steep. The cost structure of innovative biologics is naturally high fixed cost and low marginal cost: R&D, CMC, and registration are large upfront sunk/fixed costs. Once a drug is approved and scales, the marginal cost of each additional unit is low, and gross margin is generally above 85%–90%. That means once LP-003 rhinitis is approved and revenue crosses breakeven, the company could move from "loss" to "profit" abruptly, with profit elasticity far higher than revenue elasticity. This is an inflection effect from loss to profit, not the linear manufacturing pattern of "revenue rises a little and margin rises a little." The report itself defines the source of elasticity this way: LongBio's profit elasticity is "not in the traditional logic where margin jumps as revenue rises, but in whether LP-003 is approved, when it is approved, and whether it can contribute the first truly meaningful drug revenue after approval."

  A ready reference is the peer named in the report. Qyuns-B (02509.HK) crossed this line in 2025: revenue jumped from about 160 million to 807 million (about 4.08 times year on year), while gross profit grew 6.75 times, gross margin rose to 88.5%, and the company turned from loss to full-year net profit of about 307 million yuan. Note the point here: gross-profit growth (6.75 times) was clearly faster than revenue growth (4.08 times). That is a live example of the operating leverage created by a high-fixed/low-marginal-cost structure near breakeven. If LongBio commercializes successfully, it could theoretically follow a similar path. This is also the logic behind the report's optimistic scenario (HK$141.5 per share), where the valuation shifts from a "R&D story" to a "commercialization story."

  But before that inflection point arrives, any "revenue +10% → profit +X%" elasticity calculation is castles in the air. For elasticity to be delivered, the company must first have that "first revenue." That is precisely LongBio's most fragile and uncertain link. The report repeatedly emphasizes that value is highly concentrated in LP-003, and the most fragile assumption is whether its rhinitis indication can form BLA submission and approval expectations around 2026Q3 as planned. If it is delayed or fails to scale after approval, the corresponding maximum loss risk is 40%–60%, and the valuation will be pushed back to that of a "high-cash-burn clinical-stage biotech." So the right way to assess LongBio's elasticity is not to apply a multiple, but to watch the first hard indicators listed in the report: whether the LP-003 rhinitis BLA is submitted and accepted on schedule, and the uptake slope in the first full commercial year after approval. Once those happen and move in the right direction, "high elasticity" can move from paper assumption to reality. Until then, its elasticity can only be described honestly in one sentence: negative cash consumption now, very steep upside if future uptake arrives, but the inflection point has not arrived and cannot be quantified.

  Jun 4, 2026
• QHas the market already discovered this company? Or has it not realized all this yet?

  A

  Conclusion first: this is not an "undiscovered cheap stock." On the contrary, it has already been highly discovered, even enthusiastically chased, in the IPO subscription market. What has not been fully priced is the difficulty of turning clinical advantage into commercial advantage. So the question of whether "the market has discovered it" has to be split into two layers. At the sentiment/capital-flow level, it has been discovered long ago. At the fundamental/long-term value level, pricing may be too optimistic rather than too low.

  Layer 1: IPO subscription and sentiment. It has already been highly discovered, and was aggressively chased. LongBio's offering was not cold at all. The public offering was oversubscribed by about 4470 times and received about 268,000 applications. Cornerstone investors took nearly half of the offering shares (about 49.96%) with 87 million dollars, including specialist healthcare funds such as OrbiMed as well as Ruiyuan, Fullgoal, Value Partners, and others. In other words, both retail investors and institutions have already turned their attention to this company. Look at valuation as well: the IPO price of HK$96.06 implies a market cap of about HK$7.127 billion, about 3.1 times higher than the 2025 Series C post-money valuation. This is absolutely not a valuation for a company "forgotten by the market and lying on the floor." At the sentiment layer, it is hard to say the market "has not realized it yet."

  Layer 2: fundamentals and long-term value. The market has discovered the "story," but may not have fully priced the "risk." The real question is: what exactly is the market chasing? The report's view is that current trading is mainly around a three-layer narrative: LP-003's first commercialization opportunity in China's large allergy market, best-in-class imagination supported by head-to-head data versus omalizumab, and the reopening of Hong Kong's 18A IPO window. These are real signals (the Phase III seasonal allergic rhinitis trial has completed enrollment, BLA submission is planned before 2026Q3, and CSU Phase II showed a week 12 UAS7=0 rate of 66.7% in the 200mg Q8W group versus omalizumab's 43.6%). But the report repeatedly stresses a fact that sentiment can easily cover up: clinical advantage does not equal commercial advantage. Doctor prescribing, medical-insurance/payment access, and sales-organization buildout have not been tested in reality, and as of the prospectus the company still has zero revenue and zero profit, with value highly concentrated in a single product, LP-003.

  So where is the expectation gap more likely to sit? On the optimistic side, not in underestimation. The report gives conservative intrinsic value of HK$67.4 and a neutral scenario of HK$95.7, while the IPO price of HK$96.06 lands almost exactly on the neutral scenario. That means the offering price has already priced in "BLA progresses on schedule and the first product probably succeeds," leaving basically zero margin of safety (the ideal buy price is set at ≤HK$54). The report therefore assigns a Watch rating. Its core point is simple: LP-003 is close to BLA and has eye-catching data, but the offer price has already pulled forward a fair amount of success expectation. The likely market misjudgments are stated directly in the report: treating clinical advantage as an automatic substitute for commercial advantage, and equating a "long runway" with "high returns."

  One-sentence answer to this question: the market has already "discovered" LongBio, and very warmly. But it has discovered an appealing clinical story and a scarce IPO target; it may not have fully discovered the unfulfilled risks around approval timing, uptake slope, and payment access. The more useful investor reminder is not "go find a bargain," but the reverse: when sentiment is hot and valuation is no longer cheap, watch closely whether LP-003's rhinitis BLA is submitted and accepted on schedule, and whether the post-launch commercialization team and access work make real progress. These hard indicators are the yardstick for whether "heat" deserves to be called "value."

  Jun 4, 2026